A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)
Public ClinicalTrials.gov record NCT02187861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison With BR Alone or GDC-0199 Plus Rituximab (R) in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
Study identification
- NCT ID
- NCT02187861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 163 participants
Conditions and interventions
Conditions
Interventions
- Venetoclax Drug
- Bendamustine Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Sep 26, 2016
- Completion
- Mar 15, 2018
- Last update posted
- Jun 4, 2019
2014 – 2018
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Mobile | Alabama | 36608 | — |
| Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| UCLA School of Medicine; Hematology/Oncology | Los Angeles | California | 90095 | — |
| Nothwest Georgia Oncology Centers P.C | Austell | Georgia | 30106 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Illinois at Chicago College of Medicine | Chicago | Illinois | 60612-7302 | — |
| Primary Healthcare Associates SC - Harvey | Harvey | Illinois | 60426 | — |
| University of Kansas; Medical Center & Medical pavilion | Westwood | Kansas | 66205 | — |
| Sidney Kimmel Comp Cancer Ctr | Baltimore | Maryland | 21231-1000 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| James P. Wilmot Cancer Center | Rochester | New York | 14642 | — |
| University of Pennsylvania; School of Medicine | Philadelphia | Pennsylvania | 19104 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| University of Virginia | Charlottesville | Virginia | 22903 | — |
| VCU Massey Cancer Center | Richmond | Virginia | 23298-003 | — |
| West Virginia Uni Med. Center - Robert Byrd Health Science | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02187861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 4, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02187861 live on ClinicalTrials.gov.